The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

A growing body of research is finding a robust link between diet and sleep quality. But it’s not just the usual suspects like ...

However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Major health insurance providers in India — both public and private — exclude sleep disorders from their plans. This coverage ...

Adults with obstructive sleep apnea (OSA) are at increased risk for vertigo and vestibular dysfunction, relative to those without OSA.

Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...